Physician profile
Jay D Geller
NPI 1548261266
$2,468.33
in general payments reported to CMS, 2019-2025
25 companies · $241 in 2025
The $241 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $899 · 2021: $227 · 2022: $322 · 2023: $267 · 2024: $214 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $707 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $706.53 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $761.40 | 2020 | |
| Sun Pharmaceutical Industries INC. | $238.94 | 2021-2023 | Ilumya, Winlevi |
| Pfizer INC. | $207.06 | 2019-2024 | |
| Incyte Corporation | $174.54 | 2021-2024 | Opzelura |
| Novartis Pharmaceuticals Corporation | $163.98 | 2023-2025 | |
| Genzyme Corporation | $141.08 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $109.96 | 2019-2024 | Jublia, Arazlo, Cabtreo |
| Leo Pharma INC. | $98.62 | 2019-2022 | |
| Amgen INC. | $87.09 | 2020-2022 | |
| Galderma Laboratories, L.P. | $79.36 | 2019-2025 | Nemluvio |
| Abbvie INC. | $68.15 | 2023-2025 | |
| Botanix Sb INC | $55.11 | 2025 | Sofdra |
| Lilly USA, LLC | $54.94 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $46.94 | 2019 | |
| Aclaris Therapeutics, INC. | $23.57 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $20.99 | 2025 | Zoryve |
| Convatec INC. | $18.30 | 2023 | |
| Ucb, INC. | $17.70 | 2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $15.96 | 2025 | Dupixent |
| Allergan, INC. | $15.59 | 2019 | |
| Vyne Pharmaceuticals INC. | $14.83 | 2020 | |
| Revance Therapeutics, INC. | $14.07 | 2025 | Daxxify |
| E.R. Squibb & Sons, L.L.C. | $14.05 | 2024 | Sotyktu |
| Dermira, INC. | $13.32 | 2019 | |
| Almirall LLC | $12.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Geller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.